Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,510.01 92.48 0.64%
TOPIX 1,170.18 3.59 0.31%
HANG SENG 22,760.24 64.23 0.28%

Conference Calls, New Appointments, Upcoming Presentations, Prospectus Filings and Acquisition Deal Updates - Research Report on



Conference Calls, New Appointments, Upcoming Presentations, Prospectus Filings
     and Acquisition Deal Updates - Research Report on Johnson & Johnson,
                   WellPoint, Regeneron, Onyx, and MannKind

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, September 23, 2013

NEW YORK, September 23, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Johnson &
Johnson (NYSE: JNJ), WellPoint Inc. (NYSE: WLP), Regeneron Pharmaceuticals
Inc. (NASDAQ: REGN), Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX), and MannKind
Corporation (NASDAQ: MNKD). Today's readers may access these reports free of
charge - including full price targets, industry analysis and analyst ratings -
via the links below.

Johnson & Johnson Research Report  

On September 17, 2013, Johnson & Johnson (JNJ) announced that the Company will
host a conference call for investors to review its Q3 2013 financial results,
on October 15, 2013 at 8:30 a.m. ET. The Company informed that Michel
Orsinger, Worldwide Chairman of DePuy Synthes Companies, Dominic J. Caruso,
Vice President, Finance and CFO, and Louise Mehrotra, Vice President, Investor
Relations, will host the call. Interested parties may access the conference
call via its website. Also, JNJ informed that the earnings webcast is
optimized for mobile streaming on iOS devices, such as the iPhones, iPods, and
iPads. In addition, the webcast and podcast replay of the call will be
available approximately two hours after the conclusion of the conference call.
The Full Research Report on Johnson & Johnson - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.analystscorner.com/r/full_research_report/07a8_JNJ]

--

WellPoint Inc. Research Report

On September 17, 2013, WellPoint Inc. (WellPoint) announced the appointment of
John Short and Elizabeth (Liz) Tallett to the Company's Board of Directors,
effective September 18, 2013 and October 1, 2013, respectively. According to
the Company, Ms. Tallett is a Principal of Hunter & Partners, LLC, a health
care consulting firm, while Mr. Short is the former CEO of RehabCare Group, a
rehabilitation services provider. The Full Research Report on WellPoint Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/64cd_WLP]

--

Regeneron Pharmaceuticals Inc. Research Report    

On September 17, 2013, Regeneron Pharmaceuticals Inc. (Regeneron) announced
that it will present the results from Phase 3 VIVID and VISTA trials EYLEA
(aflibercept) Injection in Diabetic Macular Edema (DME) at an oral session
during the upcoming annual meeting of the Retina Society. The Presentation is
scheduled to take place on September 27, 2013 at 4:51 p.m. PDT, in Los
Angeles, US. In addition, Regeneron will also present the same data at the
EURETINA Congress in Hamburg, Germany on the same day, September 27, 2013 at
3:58 p.m. CEST. The Company further informed that it will host a webcast
investor meeting on September 28, 2013 at 7:00 a.m. PDT/10:00 a.m. EDT to
discuss the aforementioned data. The Full Research Report on Regeneron
Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/8ea7_REGN]

--

Onyx Pharmaceuticals, Inc. Research Report  

On September 18, 2013, Onyx Pharmaceuticals Inc. (Onyx) announced that the
waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976,
as amended (HSR), in connection with Amgen Inc.'s (Amgen) proposed acquisition
of Onyx, was terminated on September 18, 2013 by the United States Federal
Trade Commission. Earlier, on August 25, 2013, the two companies had announced
an agreement under which Amgen would acquire all of the outstanding shares of
Onyx for $125 per share in cash, with the transaction to be effected through a
tender offer. According to Onyx, the termination of the HSR waiting period
satisfies one of the conditions to consummate the tender offer, while other
closing conditions are yet to be satisfied, including a minimum tender of at
least a majority of outstanding Onyx shares on a fully diluted basis.
According to Onyx, the tender offer will expire on October 1, 2013, unless it
is extended in accordance with the terms of the merger agreement between the
two companies. The Full Research Report on Onyx Pharmaceuticals, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/fcf2_ONXX]

--

MannKind Corporation Research Report  

On September 18, 2013, MannKind Corporation's stock advanced 0.49%. The stock
fluctuated from $5.78 to $5.95 before ending the day at $5.90. Also, on the
same date, the Company filed a Form S3 Registration Statement under the
Securities ACT of 1933 with the Securities and Exchange Commission. According
to the Company, the said prospectus relates to the sale or disposition from
time to time of up to a maximum of 12 million shares of the Company's common
stock that may be issued upon conversion of senior secured convertible notes,
or Notes, held by Deerfield Private Design Fund II, L.P. and Deerfield Private
Design International II, L.P. (selling stockholders). The selling stockholders
acquired the Notes from the Company in private placements that closed on July
1, 2013 and September 5, 2013. Mannkind also stated that they are not selling
any common stock under the prospectus and will not receive any of the proceeds
from the sale of its common stock by the selling stockholders. The Full
Research Report on MannKind Corporation - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/044e_MNKD]

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement